ACADIA PHARMACEUTICALS INC — Director's Dealing 2021

Jan 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2021-01-06

Reporting Person: Stankovic Srdjan R. (President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-06	Common Stock	M	5444	—	Acquired	21972	Direct
2021-01-06	Common Stock	S	1725	$53.34	Disposed	20247	Direct
2021-01-07	Common Stock	M	61619	$35.80	Acquired	81866	Direct
2021-01-07	Common Stock	S	61619	$55.1159	Disposed	20247	Direct
2021-01-08	Common Stock	M	13381	$35.80	Acquired	33628	Direct
2021-01-08	Common Stock	M	12864	$21.28	Acquired	46492	Direct
2021-01-08	Common Stock	M	3488	$18.12	Acquired	49980	Direct
2021-01-08	Common Stock	S	29733	$55.2192	Disposed	20247	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-06	Restricted Stock Units	$	M	5444	Disposed		Common Stock (5444)	Direct
2021-01-06	Stock Option (Right to Buy)	$35.80	M	61619	Disposed	2027-09-06	Common Stock (61619)	Direct
2021-01-08	Stock Option (Right to Buy)	$35.80	M	13381	Disposed	2027-09-06	Common Stock (13381)	Direct
2021-01-08	Stock Option (Right to Buy)	$21.28	M	12864	Disposed	2028-10-14	Common Stock (12864)	Direct
2021-01-08	Stock Option (Right to Buy)	$18.12	M	3488	Disposed	2028-11-18	Common Stock (3488)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2020.

F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.77 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F6: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

F7: 25% of the shares subject to the Stock Option vested and became exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

F8: 25% of the shares subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

F9: 25% of the shares subject to the Stock Option vested and became exercisable on November 19, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.